missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human LTB4R (aa 297-350) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (61%), Rat (61%). This recombinant protein control fragment may be used for blocking experiments. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
LTB4R (Leukotriene B4 Receptor) is a member of the GPCR family. It is a receptor for leukotriene B4, a potent chemoattractant involved in inflammation and immune response. It has been reported in blood, bone marrow, brain, heart, liver, and skeletal muscle. In addition, it has been shown to be highly expressed in leukocytes and lymphoid tissues such as spleen, thymus, and lymph node. ESTs have been isolated from B-cell/lung/testis, breast, colon, eye, kidney, skin, spleen, testis, and tonsil libraries.
Specifications
Specifications
| Accession Number | Q15722 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 1241 |
| Name | Human LTB4R (aa 297-350) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | BLT; BLT1; BLT-1; BLTR; Chemoattractant receptor-like 1; chemokine receptor-like 1; CMKRL1; G protein-coupled receptor 16; GPR16; G-protein coupled receptor 16; leukotriene B4 receptor; leukotriene B4 receptor 1; LTB4 receptor; Ltb4r; LTB4-R 1; Ltb4r1; LTB4-R1; LTBR1; mBLTR; P2RY7; P2Y purinoceptor 7; P2Y7; purinergic receptor P2Y, G-protein coupled, 7 |
| Common Name | LTB4R |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction